Introduction
There is widespread concern about excessive use of antibiotics and its role in increasing resistance levels. [1] [2] [3] Approximately half of all antibiotic prescribing in general practice is for respiratory infection 4 and is frequently empirical, with no attempt at a microbiological investigation. This seems paradoxical as most community respiratory infection is viral in aetiology. 5 The Audit Commission has described much prescribing of antibiotics by general practitioners (GPs) as irrational and unnecessary. 6 The objective of this study was to determine whether the use of the clinical microbiology laboratory can lead to more rational antibiotic therapy for lower respiratory tract infection in general practice.
Materials and methods
The data came from a multicentre trial with an open 2 2 factorial design ( Figure) . The trial compared amoxycillin with cefaclor MR in the treatment of lower respiratory tract infection. Fifty-three patients were randomized to receive immediate antibiotic treatment with cefaclor MR or amoxycillin while 45 patients had their treatment delayed until an overnight bacteriological assessment was made of their sputum sample. Those patients randomized to overnight accelerated bacteriological evaluation (ABLE) were also randomized to receive one or other of the study drugs. However, they received an antibiotic only if their sputum sample was found to be positive for a respiratory pathogen after overnight culture by standard laboratory methods. The only pathogens considered significant were Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Samples were incubated for 48 h in 5% CO 2 on blood and chocolate agar and on gentamicin blood agar anaerobically. All samples were culture positive within 15 h, although two samples where mixed pathogens were present only yielded one isolate by 15 h. Those patients whose sputum sample contained no respiratory pathogen received no antibiotic treatment. The study was approved by the Grampian Ethics Committee.
A three-month assessment of patients' medical records was made by the study nurse. The efficacy of the treatment regimen was assessed in terms of cure (elimination of signs and symptoms of infection with no recurrence within the post-therapy period), improvement (significant but incomplete resolution of signs or symptoms of infection), relapse (worsening of signs and symptoms of infec- tion following initial improvement) and failure (signs and symptoms did not subside or improve during therapy). In addition to these outcomes, records were also kept of any adverse change in the patient's physical or mental wellbeing occurring during the three-month post-assessment period, any repeat GP visits or hospitalizations, and any concomitant medication being taken by patients.
The analysis of outcome compared: (i) the overall efficacy in terms of cure rates in patients undergoing ABLE compared with immediate antibiotic treatment; (ii) the number of repeat GP visits per patient in those having ABLE compared with immediate antibiotic treatment; and (iii) the number of repeat GP visits in those ABLE patients receiving antibiotics compared with patients receiving immediate antibiotic treatment.
The cost analysis requires a comparison to be made between the resource costs of ABLE with any resource savings. The resource costs of ABLE include the cost of sterile containers, consumables, labour, telephone, and the cost to patients of repeat GP visits to collect prescriptions. These data were collected from a patient questionnaire and the microbiology laboratory. The resource savings include savings in drug costs, dispensing fees and in GP time as a result of fewer consultations.
In comparing the two arms, costs that are common to both are not relevant to the analysis. The relevant cost differences include repeat visits to the GP (including costs to patients), concomitant medication and other health service costs. However, the only other health service cost noted at the three-month assessment was a one-week hospitalization for one patient from the immediate treatment arm. Since the average cost of a one-week in-patient stay at the Aberdeen Royal Hospitals NHS Trust was £1661, 7 it was felt that the inclusion of this in the analysis would distort the true picture.
In order to cost repeat GP visits, a cost per consultation was estimated from Unit Costs of Community Care 1995. 8 This was added to the average cost incurred by patients when visiting their GP. This was calculated from information collected in a patient cost questionnaire and comprises out-of-pocket travel expenses and the value of time spent travelling. For private transport, a cost per mile of 22.3 pence was used. The value of time was taken to be the value of leisure time, which is estimated as 40% of the value of work time. 9 Average hourly net earnings data for Grampian region 10 were used to estimate the value of work time. On the basis of these data, the value of leisure time was estimated to be 3.4 pence per minute. The sum was multiplied by the number of additional visits per patient made by immediate treatment patient compared with ABLE patients.
The delivery of specimens was not included in the cost estimates. This was based on the assumption that no additional delivery costs will be incurred since the laboratory operates a 24 h shift system and transportation of other samples is already taking place morning and evening.
In addition to information on costs, data were also collected in the ABLE arm on patients' satisfaction with their treatment. Patients whose sputum sample was positive were asked how satisfied they were with having to return the next day in order to get their prescription. Patients whose sputum sample was negative, and who therefore would not have benefited from an antibiotic, were asked how satisfied they were with not receiving an antibiotic. Patients were given the option of expressing five different levels of satisfaction, ranging from very satisfied to very dissatisfied. Table I shows differences in cure rates and repeat GP visits between ABLE and immediate treatment. Since there was no significant difference between the two antibiotics in terms of cure rates (using a Fisher's exact test), the data were pooled. Using a chi-squared test with one degree of freedom, the pooled data revealed no significant difference in cure rates between ABLE (5/43) and immediate treatment (6/53) arms.
Results and discussion
Within the two arms there was no significant difference between the two antibiotics in terms of the numbers of patients making repeat GP visits (Fisher's exact test), and so again the data were pooled. As can be seen from Table  I , the immediate treatment patients made on average 0.278 more repeat GP visits than ABLE patients, and 0.371 more repeat GP visits than ABLE patients receiving an antibiotic. Tests of difference in means reveal that both of these differences are statistically significant (P 0.049 and P 0.011, respectively). Most repeat GP visits for lower respiratory infection are due to continuation of symptoms. 11 There is an accepted relationship between viral respiratory tract infection and secondary bacterial infection. 12 However, we know of no evidence that prophylactic antibiotics can prevent this. Nevertheless, there is concern that those with a presumed viral infection who do not receive antibiotics would have more repeat GP visits due to continuation of symptoms from secondary bacterial infection than if they had received an antibiotic. If it is assumed that the proportion of patients with a viral infection is the same in both arms, then it would appear that the absence of antibiotic treatment did not lead to an increased incidence of secondary infection.
The cost difference between the ABLE and immediate treatment arms as a result of the difference in repeat GP visits was £2.59 per case. A test of difference in means showed no statistically significant difference between the arms in terms of the cost of concomitant medication (P 0.31) and therefore these costs have been omitted from the remainder of the analysis.
The resource implications of ABLE are summarized in Table II . The cost per patient of ABLE was estimated as £3.38. The use of ABLE would be anticipated to generate a net saving whichever antibiotic is prescribed. Given that there was no difference in clinical outcome between ABLE and immediate treatment, the evidence suggests that the use of ABLE would improve antibiotic therapy for lower respiratory tract infection in general practice.
Forty of the 45 ABLE patients responded to the satisfaction questions. Of these, ten were satisfied, 27 were neither satisfied nor dissatisfied, and three were dissatisfied. All three patients who were dissatisfied had had a negative sputum sample and thus had not received an antibiotic. One of these expressed concern that the sputum test would show something serious. The remaining two were unhappy at not receiving an antibiotic.
The data analysed here are specific to a particular location (Grampian). Elsewhere specimen transport costs may be incurred, the costs of bacteriological investigation may be higher, or laboratories may not be able to process specimens overnight. Thus it is possible that rather than saving resources, ABLE may incur a net cost. However, it may be worth incurring these extra costs in order to reduce unnecessary exposure to antibiotics, 13 the benefits of which include reduced side effects for patients and reduced selective pressures on antibiotic resistance.
If ABLE is indeed worthwhile for the management of lower respiratory tract infection in general practice, it may be worth considering its use in the management of other conditions, such as pharyngitis and urinary tract infections. 
